Key words rheumatism - pregnancy - lupus erythematosus - antiphospholipid antibodies - arthritis
- vasculitis
1 Introduction
Anti-cellular autoantibodies (directed against human cell membranes, cellular and/or
nuclear structures) may be circulating in the body years (!) before there is any clinical
diagnosis of an
autoimmune disease [1 ]. They can occur in the context of pathologies such as systemic lupus erythematosus
(SLE), Sjögrenʼs syndrome, systemic sclerosis,
dermatomyositis and rheumatoid arthritis. Antiphospholipid antibodies (aPL) may appear
as a secondary or even primary aspect of disease and can lead to antiphospholipid
antibody syndrome (APS)
with varying clinical presentations, principally in the form of thromboembolic events
and complications of pregnancy. Pregnant women and their children who receive certain
of these
autoantibodies by transplacental transmission are exposed to particular risks (ranging
from recurrent miscarriage, severe placental insufficiency and its attendant dangers
for mother and
infant to congenital lupus). Immunosuppressive therapy to maintain remission of the
underlying disease is essential, particularly for SLE, before planning a pregnancy.
Appropriate planning can
often significantly reduce the risks for mother and child.
Conversely, the physiological changes of pregnancy may affect the course or the clinical
appearance of rheumatic disease. For example, pregnancy-induced hypercoagulability
may increase the
risk of thrombosis which was possibly already present due to underlying disease. Normal
changes of pregnancy (incl. chloasma gravidarum, anemia, diffuse arthralgias) may
be wrongly interpreted
as symptoms of the underlying rheumatic disease. Obtaining a differential diagnosis
which differentiates preeclampsia and HELLP from flare-ups of lupus nephritis, vasculitis
or a renal crisis
in the context of systemic sclerosis requires interdisciplinary cooperation.
Most available studies are observational studies or, rarely, randomized controlled
studies of usually small patient cohorts. The result is that many recommendations
in this field are based
less on evidence and more on expert opinions.
2 Methods
For this paper, the recommendations of relevant medical associations, specialist conferences
and institutions on rheumatic disease in persons of child-bearing age with a special
focus on
lupus erythematosus and antiphospholipid syndrome were reviewed in March 2023 and
evaluated to see whether they still reflected current knowledge. The literature included
recommendations and
statements by the following organizations, institutions and authors: the European
League Against Rheumatism (EULAR) [2 ], [3 ], [4 ], the American College of Rheumatology Guideline (ACR) [5 ], the 16th International Congress on
Antiphospholipid-Antibodies Task Force Report [6 ], the British Society for Rheumatology [7 ], and the German Society for
Rheumatology [8 ].
In addition, meta-analyses, systematic overviews, guidelines, and other relevant publications
(published between 1993 and 2022) were searched and evaluated. No systematic search
and
evaluation of evidence was carried out. The statements drafted after intensive debates
therefore correspond to the level of evidence of an expert opinion. How the recommendations
are worded is
largely derived from the wording of guidelines, whereby “must” indicates a strong
recommendation and “should” a moderate recommendation. The recommendations for action
include the basis for
the recommendation as well as relevant background information to provide a better
understanding of the individual recommendations and/or their implementation in practice.
3 General Recommendation
AGG Recommendation (1)
Patients with rheumatoid disease who wish to have children should be informed that
active inflammation – irrespective of the site where it manifests (e.g., joints, skin,
internal organs such as kidneys, bowels) – is an unfavorable predictor for the course
of
pregnancy.
Well-controlled disease activity is correlated with significantly better courses of
pregnancy.
The patientʼs medication must be adjusted to take account of the wish to have children/the
pregnancy, and reliable contraception may be (temporarily) necessary.
Higher doses of folic acid (5 mg/d) in women with risk factors such as diabetes, obesity,
a medical history of risk factors for neural tube defects or taking sulfasalazine
should
already be initiated prior to conception.
If there are identifiable risks of thromboembolism, an appropriate thromboembolism
prophylaxis individualized according to the recommendations in the guidelines is necessary
during
pregnancy and/or breastfeeding.
Administration of ASA 150 mg/d in the evening from week 11 of pregnancy is recommended
as preeclampsia prophylaxis; patients with antiphospholipid syndrome should additionally
receive
low molecular-weight heparin.
Background information
Individual risks may be identified, assessed and a treatment plan set up based on
the patientʼs medical history and clinical and laboratory tests. The obstetrician
should also be familiar
with the basics of serological and rheumatic test results and rheumatology treatment
strategies to provide the appropriate care to women with autoantibodies and/or a relevant
clinical
diagnosis and be able to evaluate their risks.
AGG Recommendation (2)
Already prior to conception, obstetricians and rheumatologists should investigate
the severity of disease, its activity, and compatible medications (if necessary, together
with
hemostaseology specialists, nephrologists, and cardiologists) and inform the patient
about her individual risk profile with regards to complications of pregnancy.
AGG Recommendation (3)
Women with SLE, antiphospholipid syndrome, Sjögrenʼs syndrome, systemic sclerosis
and rheumatoid arthritis should be tested for autoantibodies (SS-A/SS-B, lupus anticoagulant,
anticardiolipin, anti-β2-glycoprotein I) which are relevant for pregnancy at least
once prior to or in the first trimester of pregnancy.
AGG Recommendation (4)
If the pregnancy is unplanned, persons with the relevant expertise (rheumatologists,
obstetricians) should be involved without delay to determine the appropriate medication
and the
pregnancy risks as well as the timing of the necessary check-ups.
4 Pregnancy and Lupus Erythematosus
4 Pregnancy and Lupus Erythematosus
4.1 Preconception counselling
Background information
Large study cohorts have clearly shown that the course of pregnancies conceived and
carried by women with active lupus disease, especially those of women with active
lupus nephritis, is
worse and includes higher numbers of early miscarriages, preterm births, and higher
rates of preeclampsia. The longer SLE is in remission and the patient is receiving
suitable therapy, the
better the prognosis [9 ].
The importance of SLE activity on the course of pregnancy is well known. Rheumatologists
use different indices, based on differently weighted clinical and laboratory parameters,
to
determine disease activity. One of the most common indices is SLEDAI (= Systemic Lupus
Erythematosus Disease Index): a score of ≥ 4 in the 6 months prior to conception is
associated with
disease flare-ups and preeclampsia [9 ]. Moreover, a flare-up during pregnancy is predictive for preterm birth or miscarriage.
The highest risk for preterm
birth and preeclampsia is when a combination of high clinical and serological activity
is present (hypocomplementemia or high levels of DNS antibodies) [10 ].
The prospective multiethnic PROMISSE observational study (= Predictors of Pregnancy
Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus)
carried out in
the USA investigated predictive factors for complications of pregnancy in women with
stable SLE [11 ]. One third of patients had inactive kidney involvement
with no functional limitations when they were pregnant, 60% were taking hydroxychloroquine
(HCQ). More than 80% of pregnancies had no complications. 19% of the women experienced
loss of
pregnancy or preterm birth related to hypertensive complications. Predictors for a
poor outcome included higher clinical SLE activity at conception, lupus anticoagulant
positivity, non-white
ethnicity, taking antihypertensives, and thrombocytopenia. An early history of lupus
nephritis (LN) and low C4 complement levels in early pregnancy were independently
associated with a risk
of renal flare [8 ], [12 ]. A first manifestation of lupus nephritis was rare and occurred in just 2% [12 ].
A Brazilian study of women with proliferative class III/IV lupus nephritis reported
more SLE flare-ups and activity during pregnancy and even after the birth, which resulted
in
significantly more hospitalizations and higher rates of preeclampsia [8 ], [13 ].
In summary, the risk of a renal flare is highest if women have active LN in early
pregnancy. The risk is lowest for women who have been in remission for a long time.
The most favorable time to plan a pregnancy is when LN is inactive (for at least 6
months and therapy is compatible with pregnancy), proteinuria values are < 0.5 g/24 h,
and renal
function and blood pressure are both normal [8 ].
AGG Recommendation (5)
Depending on maternal factors (e.g., renal involvement), a pregnancy should be planned
after a period of at least 6 months during which SLE was inactive or mildly-to-moderately
stable.
4.2 Risk of preeclampsia
Background information
The preeclampsia risk is significantly higher for women with SLE. It is even higher
for women with LN and antiphospholipid antibodies [14 ]. A systematic
search of the literature (10 studies with 6389 SLE patients) confirmed that the risk
of developing preeclampsia was about 3 times higher compared to healthy controls [15 ]. In a Californian birth registry, hypertensive complications of pregnancy in women
with SLE accounted for around 30% of preterm births and
small-for-gestational-age infants [16 ]. Data from a Norwegian birth registry additionally showed that the probability of
PE in women with active SLE was
significantly higher compared to women with inactive SLE [17 ]. LN, higher doses of glucocorticoids, antiphospholipid antibodies and arterial hypertension
are
therefore all risk factors [8 ].
AGG Recommendation (6)
A patient with SLE, especially if antiphospholipid antibodies are also present, must
be informed that her risk of preeclampsia is almost 3 times higher compared to healthy
women (with an
associated risk of FGR, IUGR, IUFD, placental insufficiency and preterm birth).
4.3 Prepartum management
4.3.1 Immunosuppression during pregnancy
The EULAR regularly publishes evidence-based recommendations on therapies during pregnancy
and breastfeeding [4 ]. Ideally, a patient with SLE will continue
with compatible immunosuppression and HCQ intake during pregnancy. Controlled studies
have shown that women who continued to take HCQ during pregnancy had fewer flares
and required fewer
steroids [18 ]. A retrospective clinical observation showed that the preeclampsia rate was lower
for SLE patients who continued to take HCQ (7.5 vs. 19.7,
p = 0.032) and the birthweights of their newborns were higher (2757 vs. 2542 g, p = 0.01)
compared to women who had discontinued HCQ [19 ]. A meta-analysis
which analyzed 7 prospective cohorts with a total of 668 lupus patients during pregnancy
with regards to HCQ found statistically significant positive effects in terms of reduced
lupus
activity when HCQ was taken during pregnancy and no impact on pregnancy outcomes [20 ]. Other studies have highlighted the risks of preterm birth and
thrombosis in SLE patients [21 ].
If ongoing prednisone intake during pregnancy is necessary, a low dose is recommended
(≤ 7.5 mg/d). Higher doses or methylprednisolone as well as other immunosuppressive
substances such
as azathioprine or calcineurin inhibitors (such as cyclosporine A, tacrolimus) may
be administered after a careful risk-benefit analysis to treat flares or for necessary
immunosuppression
[2 ], [8 ].
AGG Recommendation (7)
Women with SLE must continue to take HCQ in pregnancy (and if necessary, compatible
immunosuppressive substances) if they began taking it prior to conception.
4.3.2 Preeclampsia prophylaxis during pregnancy
The probability of PE is reduced by more than 60% in patients at risk for PE by the
prophylactic administration of 150 mg ASA. In the ASPRE study, women with a higher
risk of PE received
(double-blinded) either ASA (150 mg/d) or placebo (from weeks 11 – 14 until week 36
of gestation). The primary endpoint (PE with delivery of the infant before week 37
of gestation)
occurred in 1.6% (13/798) of women in the ASA group compared with 4.3% (35/822) in
the placebo group (OR for the ASA group: 0.38; 95% CI: 0.2 – 0.74) [22 ].
The effect is dose-dependent, with high rates of resistance against the effect of
ASA on thrombocyte function if the dose is less than 100 mg/d [23 ]. Taking
ASA at bedtime appears to be beneficial [24 ].
AGG Recommendation (8)
Low-dose acetylsalicylic acid (ASA) must be recommended as PE prophylaxis (150 mg
taken at night) to all women with SLE (from week 11 – 14 until the end of week 36
of gestation).
4.3.3 Monitoring during pregnancy
Abnormal C-reactive protein, a high erythrocyte sedimentation rate, a differential
blood cell count, urine analysis including the protein/creatinine ratio and anti-DNS,
complement usage
with decreasing levels of C3 or C4, transaminases and LDH may indicate a lupus flare,
even in (still) asymptomatic patients. Lupus activity indices have now also been validated
for
pregnant women with lupus disease (including the LAI-P or BILAG2004 Pregnancy Index)
[25 ], [26 ]. The angiogenesis markers
sFlt1/PlGF may be used as an indication of placental involvement to obtain a differential
diagnosis of preeclampsia. In a prospective multicenter observational study (PROMISSE),
sFlt1 in
the first trimester and the sFlt1/PlGF ratio in the second trimester were found to
be the strongest predictors for pregnancy outcomes in addition to such prognostically
relevant predictive
factors for pregnancy outcomes as medical history, status after thrombosis, preconception
lupus activity, non-white ethnicity, the need for antihypertensive medication and
thrombopenia
[27 ].
AGG Recommendation (9)
SLE disease activity should be investigated at least once in every trimester of pregnancy
based on the patientʼs medical history, a clinical examination and laboratory tests,
as a lupus
flare can significantly affect maternal prognosis and overall pregnancy prognosis.
Because of the increased risk of preeclampsia and the associated higher risk of fetal
growth restriction (see above):
AGG Recommendation (10)
In addition to routine ultrasound screening in the 3rd trimester of pregnancy, a patient
with SLE must have a biometric screening test and fetal as well as uterine Doppler
sonography at
least once every 4 weeks. First and second trimester screening including measurement
of uterine artery resistance should be offered.
AGG Recommendation (11)
Determination of Flt1 in the first trimester and the sFlt1/PlGF ratio in the second
and third trimester of pregnancy can be used as part of the differential diagnosis
to determine
prognosis when placental involvement is present.
5 Antiphospholipid Antibodies/Lupus Anticoagulants
5 Antiphospholipid Antibodies/Lupus Anticoagulants
Antiphospholipid antibodies (aPL) are immunoglobulin (Ig) isotypes G and M, which
can bind in vivo to phospholipid-protein complexes on membrane surfaces such as the
endothelium or placental
surfaces. In vitro they affect functional coagulation tests by binding phospholipids.
This is used for diagnosis, and the association with systemic lupus has led to the
coining of the term
“lupus anticoagulants”. Antiphospholipid antibodies can also be detected directly
using immunological tests (ELISA); the most important in clinical practice are cardiolipin
and
β2-glycoprotein-I antibodies.
Clinically, the asymptomatic detection of phospholipid antibodies is differentiated
from antiphospholipid syndrome. Antiphospholipid syndrome (APS) presents either as
frequent atypical venous
and arterial thromboembolisms (especially in younger people with no previously recognizable
risk factors, significant cardiovascular events, immune thrombocytopenia) or as complications
of
pregnancy (“obstetric APS”). Certain criteria must be met for a diagnosis of APS,
including tests which are positive for phospholipid antibodies or/and for lupus anticoagulants
on two separate
occasions with an interval of 12 weeks between tests [28 ].
Antiphospholipid syndrome (APS) rarely occurs as a primary idiopathic disease. Usually,
it occurs secondarily as an attendant symptom of connective tissue disease (e.g.,
SLE), rheumatic
disease (e.g., rheumatoid arthritis), tumors, infections, or as a result of taking
medication ([Fig. 1 ]) [29 ].
Fig. 1 Antiphospholipid antibody syndrome – genesis.
With catastrophic APS, thromboembolic manifestations in at least 3 vascular areas or organs appear within the space of just one week. The reported
mortality is about 50%. To obtain a
differential diagnosis, it is important to investigate primarily for disseminated
intravascular coagulation (DIC) and thrombotic microangiopathies (TMA) ([Fig. 2 ]).
Fig. 2 Antiphospholipid antibody syndrome – definitions.
To diagnose obstetric APS, a serological confirmation of a lupus anticoagulant and/or
a moderate-to-high titer of IgG/IgM cardiolipin antibodies IgG/IgM antibodies against
β2-glycoprotein-I
[28 ] is required in addition to the clinical diagnosis ([Table 1 ]).
Table 1 Laboratory definitions/risk profiles, Data from [3 ].
aCL: cardiolipin antibodies, aβ2-GP I: β2-glycoprotein-I antibodies, aPL: antiphospholipid
antibodies, Ig: immunoglobulin, ISTH: International Society on Thrombosis and Haemostasis,
LA: lupus anticoagulant
Laboratory definitions/risk profile of antiphospholipid antibodies for thromboembolic
events or complications of pregnancy
Two tests confirming the presence of antibodies/anticoagulant carried out at an interval
of at least 12 weeks are required.
Definitions (EULAR): laboratory risk constellations for thromboembolism or complications
of pregnancy
High risk
lupus anticoagulant (measured according to ISTH guidelines), or
aPL double positivity (every combination of LA, aCL or aβ2-GP I), or
aPL triple positivity (detection of LA, aCL and aβ2-GP I), or
consistently high aPL titer
Low risk
isolated aCL or aβ2-GP I with low-to-moderate titer levels, especially if confirmation
is only transient
AGG Recommendation (12)
If there is a suspicion of obstetric APS, the patient should be tested for anti-β2
glycoprotein IgG/IgM, and the antiphospholipid antibodies anticardiolipin IgG/IgM
and lupus
anticoagulants.
Background information
Antiphospholipid antibodies have been shown in different study cohorts to be distinct
risk factors for significant complications of pregnancy including loss of pregnancy,
especially in women
with SLE. In the PROMISSE study, lupus anticoagulants [27 ] were found to be associated with the highest risk for complications of pregnancy
in women with and
without SLE (RR for adverse pregnancy outcome with lupus anticoagulant positivity
was 12.15, 95% CI: 2.92 – 50.54, p = 0.0006). Other independent risk factors for aPL-positive
women are young
age, a prior history of thromboembolism, and SLE.
The European League against Rheumatism (EULAR) has defined a serological high-risk
profile for APS ([Table 1 ]) [3 ].
Excerpts of the recommendations of the EULAR for the treatment of women with antiphospholipid
antibodies/lupus anticoagulant have been adopted [3 ], [8 ] ([Table 2 ]).
Table 2 Recommendations for the therapy of women with antiphospholipid antibodies before
and during pregnancy (data from [3 ], [8 ]).
APS: antiphospholipid syndrome, aPL: antiphospholipid antibodies, HCQ: hydroxychloroquine,
LMWH: low molecular-weight heparin, LoE: level of evidence, GW: week of gestation,
SLE:
systemic lupus erythematosus
Primary prophylaxis for aPL-positive non-pregnant women
Not pregnant
Prophylactic therapy with low-dose ASA (75 – 100 mg/d) is recommended for asymptomatic
carriers of aPL (who do not meet any vascular or obstetric criteria for APS) with
a high-risk
aPL profile, with or without traditional risk factors.
Women with SLE without previous thromboembolism or complications of pregnancy
Prophylactic therapy with low-dose ASA (75 – 100 mg/d) is recommended for patients
with a high-risk aPL profile.
Prophylactic therapy with low-dose ASA (75 – 100 mg/d) is recommended for patients
with a low-risk aPL profile.
Prophylactic therapy with low-dose ASA is recommended for non-pregnant women with
a history of purely obstetric APS (with or without SLE) after weighing up the risks
and benefits
(aPL profile, other cardiovascular risk factors, tolerability of ASA).
Therapy for aPL-positive women in pregnancy
Pregnant
Treatment with low-dose ASA during pregnancy should be considered for women with a
high-risk aPL profile but without a prior history of thrombosis or complications of
pregnancy
(with or without SLE).
For women with a history of pregnancy complications from APS only (no thrombotic events),
with or without SLE:
If there is a prior history of > 3 recurrent spontaneous miscarriages before week
10 of gestation and/or miscarriage after the 10th week of gestation (without other
causes),
administering a combination of low-dose ASA (150 mg/d) and LMWH prophylactically during
pregnancy is recommended.
If there is a previous history of delivery before week 34 of gestation due to eclampsia,
severe preeclampsia, or placental insufficiency, prophylactic treatment with low-dose
ASA or a combination of ASA (150 mg/d) and LMWH is recommended which takes account
of the individual risk profile.
If the clinical criteria have not been sufficiently met for a diagnosis of prior obstetric
APS, for example, 2 recurrent spontaneous miscarriages before week 10 of gestation
or
delivery ≥ 34th week of gestation due to severe preeclampsia or eclampsia, treatment
with low-dose ASA (150 mg/d) alone or in combination with LMWH may be considered,
always
based on the individual risk profile.
If treatment consists of prophylactic doses of LMWH during pregnancy for obstetric
APS, continuing the prophylactic doses of LMWH for 6 weeks after the birth may be
considered
to reduce the risk of maternal thrombosis.
For women who meet the criteria of obstetric APS with recurrent complications of pregnancy
despite receiving a combination of LMWH and low-dose ASA (150 mg/d)
increase the LMWH dose to achieve therapeutic levels, or
administer HCQ, or
low-dose prednisolone in the 1st trimester of pregnancy, or
consider administering intravenous immunoglobulins in very specific cases.
A combination of low-dose ASA and therapeutic doses of LMWH during pregnancy and the
puerperium is recommended for APS patients with a prior history of thromboembolism.
6 Neonatal Lupus Syndrome (for Maternal Autoantibodies with or without Sjögrenʼs
Syndrome)
6 Neonatal Lupus Syndrome (for Maternal Autoantibodies with or without Sjögrenʼs
Syndrome)
The maternal autoantibodies SS-A (Ro52/Ro 60) and SS-B (La/47kd protein) are associated
with a risk of neonatal lupus (NL) in the newborn (i.e., a passively acquired autoimmune
disease). The
risk increases if maternal antibody titers (> 50, especially > 100 U/l) are high or
both autoantibodies are detected [30 ], [31 ].
These autoantibodies occur predominantly in women with Sjögrenʼs syndrome but may
also be present in patients with SLE, rheumatoid arthritis or in clinically healthy
pregnant women ([Fig. 3 ]). From around week 11 of gestation, maternal autoantibodies launch a passive transplacental
attack on the infant during its intrauterine development.
During vulnerable cardiac development stages (usually between week 16 and 24 of gestation)
this may not just lead to myocarditis, cardiomyopathy and irreversible fibrotic remodeling
of the AV
node but can also lead to cutaneous signs of disease, hepatic damage and (pan)cytopenias
in the neonate [30 ], [32 ], [33 ] ([Fig. 3 ]).
Fig. 3 Presence of autoantibodies against Sjögrenʼs syndrome autoantigens.
Clinical presentation
fetal AV block (CHB), myocarditis, cardiomyopathy
skin efflorescence typical for lupus (often triggered by UV light) which develops
postnatally in the first few weeks of life
rarely: anemia, leukopenia/thrombopenia, hepatic damage
AGG Recommendation (13)
Women with SS-A and/or SS-B antibodies should be informed about the CHB/conatal lupus
risk of 0.7 – 2%. If a woman has already given birth to one child with CHB/conatal
lupus, she should be
informed about the significantly higher risk of 15 – 20%.
6.1 Congenital AV block, cardiac involvement
The cardiac impact of NL is the most clinically important: irreversible fibrotic remodeling
of the AV nodal region with congenital AV block (CHB). The CHB risk of children born
to
SS-A/SS-B-antibody-positive mothers is 0.7 – 2% in the first pregnancy. The risk of
recurrence (the mother has already given birth to one child with NL/CHB) is significantly
higher at
15 – 20% [8 ], [32 ]. Most CHB are diagnosed in utero between week 20 and 24 of gestation. The overall
mortality is around 20%,
of which one quarter die in utero and just under half of the children die in the first
3 months of life. Two thirds require a pacemaker already as an infant. The cumulative
10-year survival
rate of a liveborn neonate with CHB is about 85%. The prognosis is mainly determined
by the concomitant cardiomyopathy (fibrotic replacement of cardiac muscle tissue/myocarditis)
[8 ], [32 ].
CHB develops within a very short time (< 24 h) and can be neither reliably predicted
with currently tested examination methods (such as mechanical measurement of PR intervals
or serial
home monitoring) [34 ] nor is it (ideally reversibly) treatable [35 ]. In most cases, the detection of CHB has no direct
clinical consequences subsequently in terms of initiating drug therapy [36 ]. This means that serial echocardiography carried out in women who are “only”
SS-A/SS-B positive with no previous history of an infant with NL or CHB only leads
to an unnecessary use of resources and maternal disquiet. However, serial screening
is recommended for
women with a high risk of CHB.
The obstetrician and neonatologist are responsible for initiating serial echocardiography
monitoring of a fetus with CHB and making the decision when to deliver the infant.
The obstetric
setting of infants with CHB requires interdisciplinary cooperation even before the
birth.
AGG Recommendation (14)
Women who are positive for SS-A and/or SS-B antibodies should be screened in the second
and third trimesters of pregnancy, and screening should include fetal echocardiography.
When
routine screening is carried out as required by the German guidelines on maternity
policy and care, bradycardia screening should be carried out every 4 weeks (e.g.,
by auscultation, CTG or
ultrasound).
AGG Recommendation (15)
Starting in week 16 – 24 of gestation, weekly monitoring of the fetal heart rate and
second and third trimester screening including fetal echocardiography should be carried
out in women
who have already given birth to a child with congenital AV block (CHB) and/or neonatal
lupus.
AGG Recommendation (16)
An infant with congenital AV block (CHB) must be delivered in a level I perinatal
center with the facilities to provide immediate cardiac emergency care.
AGG Recommendation (17)
An infant who appears to be in good cardiac health during the pregnancy born to a
mother with SS-A/SS-B antibodies should have an ECG postnatally.
6.2 Cutaneous neonatal lupus
In the first weeks of life the neonate may develop the skin efflorescence typical
for lupus due to a (passively acquired) antibody-mediated autoimmune response with
histopathological
findings such as those associated with cutaneous lupus erythematosus. Rarer diagnoses
include Coombs-positive hemolytic anemia, thrombopenia, leukopenia or organ involvement
(e.g., from
elevated transaminase levels). These presentations are usually self-limiting and disappear
within 6 – 9 months.
In prospective studies, cutaneous NL developed in 16 – 40% of infants [37 ], [38 ]. The skin presentations are usually
reversible. However, a retrospective study found sequelae in 34% of 106 children with
NL (13% had telangiectasias, 17% had disorders of pigmentation, 9% had atrophic scars)
[39 ].
AGG Recommendation (18)
Women who have already given birth to a child with CHB and/or neonatal cutaneous lupus
affecting the above-mentioned organ systems should be followed up with weekly monitoring
of the
fetal heart rate from week 16 to 24 of gestation and second and third trimester screening
should include fetal echocardiography.
6.3 Drug therapy
The antimalarial hydroxychloroquine (HCQ) has been used for decades as a well-tolerated
immune-modulating substance to treat SLEs. It reduces disease activity as well as
the required
glucocorticoid doses. The half-life of HCQ is assumed to be 50 – 60 days (probably
caused by long binding in tissue), and at low doses (< 5 mg/kg/d), the toxicity is
relatively low. The
most commonly debated risk is retinopathy, but this appears to be dose-dependent and
cumulative after 10 yearsʼ intake and occurs in just 2%. An ophthalmic examination
is therefore
recommended before or at the start of therapy, followed by annual ophthalmic examinations
over the course of therapy [40 ]. Registry data have shown that
maternal HCQ therapy reduces the risk of CHB recurrence by more than 60% [36 ]. A prospective phase-2 study has recently confirmed these data. The study
included 54 women who had previously already given birth to an infant with CHB. The
mothers were given HCQ (400 g/d) before week 10 of gestation. Four of 54 (7.4%) fetuses
went on to develop
2° or 3° CHB. This means that the CHB rate was significantly (p = 0.02) lower than
in historic cohorts [41 ]. HCQ also appears to have a protective effect
against the disease activity of SLE in the puerperium, indicating that the continued
intake of HCQ (at least for women who additionally have SLE) should be discussed [42 ].
AGG Recommendation (19)
Women who have already given birth to a child with CHB and/or neonatal lupus must
be treated with 400 mg/d HCQ starting at the latest in week 10 of gestation and continuing
until the end
of the puerperium.
AGG Recommendation (20)
Prophylactic therapy with 400 mg/d HCQ should be discussed and generously prescribed
for women who are positive for SS-A and/or SS-B antibodies.
7 Peripartum Management
AGG Recommendation (21)
A pregnancy in a woman with rheumatic disease is considered a risk pregnancy and the
care offered should be analogous to the care provided to women at risk for preeclampsia/placental
insufficiency.
AGG Recommendation (22)
Induction of labor or elective caesarean section is not indicated for women with asymptomatic
rheumatic disease. Induction of labor may be offered and recommended from week 39 + 0
of
gestation. The decision in cases with active symptomatic disease must be taken on
an individual basis.
8 Postpartum Management
8.1 Medication
There are some study data which indicate that the rate of SLE flares increases postpartum
[43 ], [44 ]. The patientʼs
individual risk of thrombosis must also be taken into consideration, especially for
women with antiphospholipid syndrome who have an increased risk of thrombosis. Please
consult current
guidelines and recommendations issued by specialist medical associations [45 ].
AGG Recommendation (23)
SLE-specific medication must be administered during pregnancy and in the puerperium.
Rheumatological control examinations at 12 and 24 weeks postpartum must be recommended.
AGG Recommendation (24)
If there is no peripartum infection from other causes, biological agents (such as
TNF-α or IL inhibitors) may be restarted 24 h after vaginal delivery or 48 h after
caesarean section.
8.2 Breastfeeding
AGG Recommendation (25)
Women must be recommended to breastfeed for at least 6 to 12 months. Disease-specific
medications must be continued using drugs compatible with lactation.
Raynaudʼs phenomenon of the nipple (extremely painful transient ischemia where the
affected area first turns white, then blue, followed by periareolar erythema) is reported
in the
literature as an underdiagnosed, often wrongly diagnosed, problem of pregnant women
and breastfeeding mothers. A number of case reports are available but there are no
systematic studies
[46 ], [47 ]. Possible trigger factors include induced digital vasospasm, cold and stress. It
is assumed that women with
rheumatic disease, for whom Raynaudʼs phenomenon of fingers and toes is often a symptom
of underlying disease, are more commonly affected. The symptoms are relatively easy
to treat, and
treatment consists of warmth or, if necessary, the administration of vasodilating
substances such as nifedipine (10 – 60 mg retard) [48 ].
AGG Recommendation (26)
Pregnant women with rheumatic disease should be actively asked about Raynaudʼs phenomenon
of the nipple, informed, and treated if necessary.
Fischer-Betz and Haase [8 ] compiled an overview of the recommendations for management pre- and post-conception,
during pregnancy, and in the postpartum
period, which has been added to by the AGG authors ([Table 3 ]).
Table 3 Recommendations for examinations and measures to be taken prior to conception, during
and after pregnancy for women with systemic lupus erythematosus
(SLE); data from [8 ], with the addition of obstetrically relevant recommendations.
a SLEDAI = Systemic Lupus Erythematosus Activity Index, a score of > 4 in the 6 months
prior to conception is associated with a higher probability of
flares/preeclampsia [1 ].
b Doppler sonography of the uterine arteries to estimate the individual risk of preeclampsia.
c Biometric tests.
d sFlt/PlGF ratio to estimate and obtain differential diagnosis of placental involvement
in the disease process.
Prior to conception
Generally
Previous pregnancies/complications of pregnancy?
Comorbidities (e.g. hypertension, diabetes, thromboembolic events)?
Vaccinations?
Take folic acid starting 4 to 12 weeks before the planned conception
Vitamin D substitution (if necessary, determine vitamin D levels)
SLE-specific
Severity of disease (especially renal, pulmonary, cardiac impact; if necessary, interdisciplinary
cooperation with a review of contraindications); review records of the last
cardiopulmonary check-up, update where necessary? Current renal values?
Review current SLE activity and SLE activity in the last 6 to 12 months (ideally with
a validated instrument, e.g., SLEDAI; target SLEDAI is ≤ 4)a
Drug therapy: contraindicated? → adjust therapy
Continue with hydroxychloroquine or initiate treatment with hydroxychloroquine
Lab tests: erythrocyte sedimentation rate (before the start of pregnancy)/C-reactive
protein, complete blood count including thrombocytes, creatinine/creatinine clearance,
LDH,
CK, liver values
Check urine status, possibly albumin excretion (protein/creatinine ratio)
Check complement (C3 and C4 or CH50) levels, DNS antibodies, SS-A/SS-B antibodies, antiphospholipid antibodies, lupus anticoagulant
In pregnancy
In every trimester of pregnancy:
Review disease activity (ideally using a validated instrument, e.g., SLEDAI)
Review/adjust therapy
Administer low-dose aspirin (150 mg/d) as preeclampsia prophylaxis, starting at the
latest between week 11 – 16 of gestation and continuing until the end of week 36 of
gestation
Long-term glucocorticoid intake: 75 g OGTT screening test
Routine ultrasound screening, additional recommendation for
first trimester screening to include Doppler sonography of the uterine arteriesb
second trimester screening to include Doppler sonography of the uterine arteriesb
third trimester: monthly biometric tests and feto-(maternal) Doppler sonographyb,c ; intensify controls if fetal growth appears to be levelling off/fetal growth
retardation is apparent; if necessary carry out additional examination using sFlt1/PlGF
ratiod
SS-A/SS-B-positive women should be screened for fetal bradycardia by a specialist
at every examination; echocardiography during first, second, and third trimester screening
is
recommended.
SS-A/SS-B-positive women: information about 1 – 2% probability of neonatal lupus syndrome
(AV block/myocarditis, cutaneous lupus)
Postpartum
SS-A/SS-B positive women: newborns should have an ECG.
After 12 and 24 weeks: SLE activity should be reviewed.
9 Rheumatoid Arthritis (rA), Seronegative Spondyloarthritis (SpA), Psoriatic Arthritis
(PsA)
9 Rheumatoid Arthritis (rA), Seronegative Spondyloarthritis (SpA), Psoriatic Arthritis
(PsA)
A systematic review combined with a meta-analysis has shown that the disease activity
of rA improves by 60% during pregnancy but worsens again by 50% postpartum [49 ]. Another meta-analysis found a 1.4 to 2.2 higher risk for poor fetomaternal outcomes
(such as increased rates of spontaneous miscarriage, gestational hypertension, preeclampsia,
SGA/FGR, preterm birth) compared to healthy controls [50 ]. There are fewer data on PsA; disease remains stable in around ⅓ of all cases during
pregnancy, is
exacerbated in ⅓ and improves in ⅓ of cases [51 ]. The data on SpA is equally controversial, with very variable courses of disease
(ranging from stable to
exacerbated) reported during pregnancy. However, what all these diseases have in common
is that a significant percentage of patients will experience worsening of disease
again in the
postpartum months [52 ]. Here too, drugs which are compatible with pregnancy and breastfeeding to control
disease activity are essential ([Table 4 ]). There has been a paradigm shift in recent years with regards to the use of TNF-α
inhibitors which have been used for more than 20 years to treat the
arthritic diseases discussed here. Most of these substances (infliximab, adalimumab,
golimumab, etanercept) have IgG structures and are transferred to the fetus through
the placenta, although
transmission of etanercept to the fetal circulation is lower due to its specific molecular
structure. The TNF blocker certolizumab, which consists of an anti-TNF PEGylated Fab
fragment, has
the lowest transmission-to-fetal-circulation rate. Nevertheless, a patient whose disease
is already controlled well with a different TNF blocker should not be switched to
certolizumab.
Certolizumab may be considered if TNFα therapy needs to be initiated in pregnancy
or if the patient wished to become pregnant [53 ].
Table 4 Antirheumatic medications in pregnancy and breastfeeding. Data from EULAR recommendations
[4 ], [8 ].
Medication
Commenta
Breastfeedinga
a After carefully weighing up the risks and benefits, and depending on disease severity
and activity after the patient has received individually tailored detailed
information.
b Based on case series of unplanned pregnancies with maternal exposure in the 1st
trimester, there does not appear to be a pattern of congenital anomalies. Can be used
in pregnancy if there is no other therapy which adequately controls disease activity.
c Biological DMARDs (disease-modifying antirheumatic drugs) for which there are no
or only limited data with regards to breast feeding should be avoided during
breastfeeding if the disease activity can be effectively controlled using other therapies.
Based on the pharmacological properties of biological DMARDs, women should not be
advised
against taking these substances when breastfeeding if no other options are available.
Non-selective COX inhibitors (classic NSAIDs)
Can be taken in the first and second trimester of pregnancy.
Compatible
Selective COX inhibitors
Should be avoided.
Celecoxib is the only selective COX inhibitor that has been sufficiently investigated;
it is compatible.
Azathioprine
Can be continued; dose of 2 mg/kg/d should not be exceeded.
Compatible
Cyclosporine
Can be continued at the lowest effective dose; dose of 2 – 3.5 mg/kg/day should not
be exceeded.
Compatible
Cyclophosphamide
Teratogenic in humans.
Discontinue 3 months prior to planned pregnancy (consider in life-threatening situations
from the 2nd trimester of pregnancy).
No data, avoid
Hydroxychloroquine
Dosages the same as outside of pregnancy.
Compatible
Chloroquine
Dosages the same as outside of pregnancy.
Compatible
Leflunomide
Teratogenic in animal studies, should be avoided.
Insufficient data for humans; a washout period is necessary before planning a pregnancy.
No data, avoid
Methotrexate
Teratogenic for humans, discontinue 1 – 3 months prior to planned pregnancy, afterwards
folic acid substitution (1 – 5 mg/d) until the 1st trimester of pregnancy.
Data insufficient, avoid
Mycophenolate mofetil
Teratogenic for humans, discontinue at least 1.5 months prior to planned pregnancy.
No data, avoid
Prednisone, prednisolone
Continue intake at lowest effective dose.
Compatible
Methylprednisolone
Can be administered during acute flare-ups.
Administer in cases of acute flare-up.
Sulfasalazine
Continue, do not exceed 2 g/d + must be accompanied by supplementation with folic
acid.
Compatible
Tacrolimus
Continue at the lowest effective dose; if necessary, adjust dose according to plasma
levels.
Compatible
Colchicine
Continue, do not exceed 1 mg/d.
Compatible
Intravenous immunoglobulin
Continue.
Compatible
Tofacitinib
Avoid, discontinue 2 months prior to conception.
No data, avoid
Infliximab
Continue until week 20 of gestation; administration possible during entire pregnancy
with rigorous monitoring.
Compatible
Adalimumab
Continue until week 20 of gestation; administration possible during entire pregnancy
with rigorous monitoring.
Compatible
Golimumab
Limited data; administration possible during entire pregnancy with rigorous monitoring
if there is no alternative.
Compatible
Etanercept
Continue until week 30 – 32 of gestation; administration possible during entire pregnancy
with rigorous monitoring.
Compatible
Certolizumab
Continue.
Compatible
Rituximab
Limited datab .
Preferably switch to a different therapy or administer shortly before conception.
Administration in the 2nd and 3rd trimester may result in B-cell depletion in the
infant.
Limited datac
Anakinra
May be continued if there are no alternatives.
No data, avoid
Ustekinumab
Limited evidence – opt for alternative drugs if possible.
No data, avoid
Belimumab
Limited datab .
Preferably switch to a different therapy; Germany has a Belimumab pregnancy registry.
No datac
TNF blockers are still detectable at low concentrations in infants several months
after the birth, which is why the intake of these substances should be paused in the
3rd trimester of
pregnancy in cases with stable disease and restarted again after the birth. There
are no long-term data about children after the 2nd–5th years of life; however, there
are currently no data
which indicate a negative immunocompromising effect. As a precaution, infants who
were exposed in utero should not be vaccinated with active vaccines in their first
months of life [54 ], [55 ]. In 2022, the EULAR recommended discontinuing adalimumab and infliximab intake around
week 20 of gestation and etanercept
intake between weeks 30 – 32 of gestation and, with little evidence, to administer
certolizumab in specific cases during entire pregnancy [53 ].
Antinuclear antibodies such as SS-A and SS-B, which have been associated with the
above-mentioned complications of pregnancy and disease, should also be monitored in
patients with rA ([Fig. 3 ]).
AGG Recommendation (27)
Women with rA, SpA and PsA should be informed at the start of their pregnancy that
their disease may be associated with a higher risk of poor fetomaternal outcomes.
Regular rheumatic
check-ups and therapy before and during pregnancy are therefore recommended to stabilize
the disease process.
AGG Recommendation (28)
Women with rA and other autoimmune diseases should, after consulting with the treating
rheumatologist, be tested once for SS-A and SS-B antibodies prior to or early in pregnancy.
Postpartum flare-ups in the months following the pregnancy occur in around half of
all women [49 ].
10 Mixed Connective Tissue Disease/Undifferentiated Connective Tissue Disease
10 Mixed Connective Tissue Disease/Undifferentiated Connective Tissue Disease
Mixed connective tissue disease is a defined disease entity with a specific autoantibody
constellation (detection of U1-RNP antibodies) and clinical signs of systemic lupus
erythematosus,
systemic sclerosis, dermatomyositis and Sjögrenʼs syndrome. The above-mentioned risks
are expected in patients with mixed connective tissue disease and antiphospholipid
antibodies, lupus
anticoagulant and/or SS-A/SS-B antibodies [56 ].
AGG Recommendation (29)
Women with mixed or other connective tissue disease should be informed, preferably
before or at the start of pregnancy, that the disease may be associated with a higher
risk of poor
fetomaternal outcomes, and that regular rheumatic monitoring and therapy before and
during pregnancy are recommended to ensure that disease activity remains stable.
AGG Recommendation (30)
Women with mixed or other connective tissue disease should be tested once for SS-A/SS-B
and antiphospholipid antibodies before conception or in early pregnancy.
11 Vasculitis
Vasculitis can affect small (e.g., granulomatosis with polyangiitis or microscopic
polyangiitis), medium-sized (polyarteritis nodosa) and large vessels (Takayasuʼs arteritis).
Behçetʼs
disease and IgA vasculitis are also considered as part of this group of rheumatic
diseases. These diseases are associated with an increased risk of preeclampsia, placental
insufficiency, SGA,
FGR, preterm birth and hypertension [57 ].
AGG Recommendation (31)
Low-dose acetylsalicylic acid (ASA) must be recommended to all women with vasculitis
(from week 11 – 14 of gestation until the end of week 36 of gestation) as PE prophylaxis
(150 mg taken
at night).
AGG Recommendation (32)
Monitoring during pregnancy and patient management peripartum and in the postpartum
period should be analogous to that provided to women at risk for hypertension, preeclampsia.
and
placental insufficiency.
EULAR has compiled a systematic overview of the existing data on experiences with
and safety aspects of common antirheumatic drug therapies during pregnancy and breastfeeding
which includes
expert consensuses [4 ]. The most important aspects of these expert consensuses are summarized in [Table 4 ].
